Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) CAO George C. Clark sold 1,915 shares of the firms stock in a transaction on Monday, December 20th. The stock was sold at an average price of $123.84, for a total transaction of $237,153.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which []
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) CAO George C. Clark sold 1,915 shares of the stock in a transaction dated Monday, December 20th. The stock was sold at an average price of $123.84, for a total transaction of $237,153.60. The transaction was disclosed in a legal filing with the SEC, which is available through this []
Equities analysts predict that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) will report earnings per share of ($1.93) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Biohaven Pharmaceuticals earnings. The highest EPS estimate is ($0.45) and the lowest is ($2.88). Biohaven Pharmaceutical posted earnings per share of ($3.62) []
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) insider Elyse Stock sold 21,919 shares of the businesss stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $105.49, for a total value of $2,312,235.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, []

Biohaven Pharmaceutical (NYSE:BHVN) Trading 5.8% Higher

12:06pm, Friday, 17'th Dec 2021 Dakota Financial News
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)s share price traded up 5.8% on Wednesday . The stock traded as high as $110.98 and last traded at $110.13. 19,051 shares were traded during trading, a decline of 97% from the average session volume of 586,234 shares. The stock had previously closed at $104.05. Several analysts have weighed []
HC Wainwright restated their buy rating on shares of Biohaven Pharmaceutical in a research note issued to investors on Tuesday, TipRanks reports. They currently have a $160.00
NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that
In last trading session, Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) saw 0.78 million shares changing hands with its beta currently measuring 0.93. Companys recent per share price level of $103.56 trading at -$5.73 or -5.24% at ring of the bell on the day assigns it a market valuation of $7.10B. That closing price of BHVNs Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Falls -5.24%, But An Additional Plunge May Follow. Read More »
Brokerages forecast that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) will post $186.03 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Biohaven Pharmaceuticals earnings, with the highest sales estimate coming in at $305.00 million and the lowest estimate coming in at $147.00 million. Biohaven Pharmaceutical reported []
Analysts forecast that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) will report $186.03 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Biohaven Pharmaceuticals earnings. The highest sales estimate is $305.00 million and the lowest is $147.00 million. Biohaven Pharmaceutical posted sales of $35.11 million during the same quarter last []
During the last session, Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)s traded shares were 0.38 million, with the beta value of the company hitting 0.93. At the end of the trading day, the stocks price was $115.55, reflecting an intraday gain of 4.69% or $5.18. The 52-week high for the BHVN share is $151.51, that puts Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Drops -31.12% From Highs, Now What? Read More »
Harbor Investment Advisory LLC increased its stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by 31.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 468 shares of the companys stock after acquiring an additional 111 shares during the quarter. Harbor Investment Advisory LLCs []
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Stock analysts at Cantor Fitzgerald increased their FY2021 EPS estimates for Biohaven Pharmaceutical in a research report issued on Wednesday, November 10th. Cantor Fitzgerald analyst C. Duncan now expects that the company will earn ($9.88) per share for the year, up from their previous estimate of ($12.25). Cantor []
NEW HAVEN, Conn., Nov. 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that enrollment is now complete in the verdiperstat arm of the HEALEY ALS Platform Trial. This first-ever platform trial in ALS, sponsored by the Sean M.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE